Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation

Journal of Experimental Medicine

Volumn 183, Issue 2, 1996, Pages 473-484

  Poignard, Pascal ^a   Fouts, Tim ^b   Naniche, Denise ^a   Moore, John P ^b   Sattentau, Quentin J ^a  

^a CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^b AARON DIAMOND AIDS RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN; EPITOPE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; NEUTRALIZING ANTIBODY; PROTEIN SUBUNIT; VIRUS ANTIBODY;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; CONFORMATIONAL TRANSITION; DISSOCIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR CLONING; PRIORITY JOURNAL; VIRUS ENVELOPE; VIRUS INHIBITION; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FLOW CYTOMETRY; GLYCOPROTEINS; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV-1; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PROTEIN CONFORMATION; VIRION;

EID: 0030023304     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.183.2.473     Document Type: Article

References (79)

1. Dimmock, N.J. 1995. Update on neutralization of animal viruses. Rev. Med. Virol 5:165-179.
2. Robert-Guroff, M., M. Brown, and R.C. Gallo. 1985. HTLV-III-neutralizing antibodies in patients with AIDS and AIDS related complex. Nature (Lond.). 316:72-74.
3. Weiss, R.A., P.R. Clapham, R. Cheingsong-Popov, A.G. Dalgleish, C.A. Carne, I.V.D. Weller, and R.S. Tedder. 1985. Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature (Lond.). 316: 69-72.
4. Lasky, L.A., J.E. Groopman, C.W. Fennie, P.M. Benz, D.J. Capon, D.J. Dowbenko, G.R. Nakamura, W.M. Nunes, M.E. Renz, and P.W. Berman. 1986. Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science (Wash. DC). 233:209-212.
5. Weiss, R.A., P.R. Clapham, J.N. Weber, A.G. Dalgleish, L.A. Lasky, and P.W. Berman. 1986. Variable and conserved neutralization antigens of human immunodeficiency virus. Nature (Lond.). 324:572-575.
6. Steimer, K.S., C.J. Scandella, P.V. Skiles, and N.L. Haigwood. 1991. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to gp120. Science (Wash. DC). 254:105-108.
7. Broliden, P.-A., A. von Gegerfelt, P. Clapham, J. Rosen, E.-M. Fenyo, R. Wahren, and K. Broliden. 1992. Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc. Natl. Acad. Sci. USA. 89:461-465.
8. Moore, J.P., and D.D. Ho. HIV neutralizations: the consequences of viral adaptation to growth on transformed T cells. AIDS. 9 (Suppl. A): S117-S136.
9. Ho, D.D., M.S.C. Fung, Y. Cao, X.-L. Li, C. Sun, T.W. Chang, and N.-C. Sun. 1991. Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. Proc. Natl. Acad. Sci. USA. 88:8949-8952.
10. Fung, M.S.C., C.R.Y. Sun, W.L. Gordon, R.-S. Liou, T.W. Chang, N.-C. Sun, E.S. Daar, and D.D. Ho. 1992. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. J. Virol. 66:848-856.
11. Moore, J.P., Q.J. Sattentau, H. Yoshiyama, M. Thali, M. Charles, N. Sullivan, S.-W. Poon, M.S. Fung, F. Traincard, M. Pinkus, et al. 1993. Probing the structure of the V2 domain of the human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: the human immune response to the V1 and V2 domains. J. Virol. 67:6136-6151.
12. McKeating, J.A., C. Shotton, J. Cordell, S. Graham, P. Balfe, N. Sulliven, M. Charles, M. Page, A. Bolmstedt, S. Oloffson, et al. 1993 Characterization of neutralizing monoclonal antibodies to linear and conformational dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120. J. Virol. 67:4932-4944.
13. Warner, S.V., A. Pinter, W.J. Honnen, M. Girard, E. Muchmore, and S.A. Tilley. 1994. A novel glycan dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent neutralizing chimpanzee monoclonal antibody. J. Virol. 68:4636-4642.
14. Shotton, C., C. Arnold, Q.J. Sattentau, J. Sodroski, and J.A. McKeating. 1995. Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein. J. Virol. 69:222-230.
15. Goudsmit, J., C. A.B. Boucher, R.H. Meloen, L.G. Epstein, L. Smit, L. van der Hoek, and M. Bakker. 1988. Human antibody response to a strain specific HIV-1 gp120 epitope associated with cell fusion inhibition. AIDS. 2:157-164.
16. Palker, T.J., M.E. Clark, A.J. Langlois, T.J. Matthews, K.J. Weinhold, R.R. Randall, D.P. Bolognesi, and B.F. Haynes. 1988. Type specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Prof. Natl. Acad. Sci. USA. 85:1932-1936.
17. Rusche, J.R., K. Javaherian, M. McDanal, J. Petro, D.L. Lynn, R. Grimaila, A. Langlois, R.C. Gallo, L.O. Arthur, P.J. Fischinger, et al. 1988. Antibodies that inhibit fusion of HIV-1-infected cells bind a 24 amino acid sequence of the viral envelope gp120. Proc. Natl. Acad. Sci. USA. 85:3198-3202.
18. Skinner, M.A., R. Ting, A.J. Langlois, K.J. Weinhold, H.K. Lyerly, K. Javaherian, and T.J. Matthews. 1988. Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. AIDS Res. Hum. Retroviruses. 4:187-197.
19. Kinney-Thomas, E., J.N. Weber, J McClure, P.R. Clapham, M.C. Singhal, M.K. Shriver, and R.A. Weiss. 1988. Neutralizing monoclonal antibodies to the AIDS virus. AIDS. 2:25-29.
20. Meloen, R.H., R.M. Liskamp, and J Goudsmit. 1989. Specificity and function of the individual amino acids of an important determinant of human immunodeficiency virus type 1 that induces neutralizing activity. J. Gen. Virol. 70:1505-1512.
21. Profy, A.T., P.A. Salinas, L.I. Eckler, N.M. Dunlop, P.L. Nara, and S. Putney. 1990. Epitopes recognized by the neutralizing antibodies of an HIV-infected individual J. Immunol. 144:4641-4648.
22. Liou, R.-S., E.M. Rosen, M.S.C. Fung, W.N.C. Sun, C. Sun, W. Gordon, N.T. Chang, and T.W. Chang., 1989. A chimeric mouse-human antibody that retains specificity for HIV gp120 and mediates the lysis of HIV-infected cells. J. Immunol 143:3967-3975.
23. Durda, P.J., L. Bacheler, P. Clapham, A.M. Jenoski, B. Leece, T.J. Matthews, A. McKnight, R. Pomerantz, M. Rayner, and K. Weinhold. 1990. HIV-1 neutralizing monoclonal antibodies induced by a synthetic peptide. AIDS Res Hum. Retrtroviruses. 6:1115-1123.
24. Gorny, M.K., J.-Y. Xu. V. Gianakakos, S. Karwowska, C. Williams, H.W. Sheppard, C.V. Hanson, and S. Zolla Pazner. 1991. Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the HIV-1 envelope glycoprotein. Proc. Natl. Acad. Sci. USA. 88:3238-3242.
25. Laman, J.D., M.M. Schellekens, Y.H. Abacioglu, G.K. Lewis, M. Tersmette, R.A.M. Fouchier, J.P.M. Langedijk, E. Classen, and W.J.A. Boersma, 1992. Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type-1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain. J. Virol. 66:1823-1831.
26. McKeating, J.A., J. Cordell, C.J. Dean, and P. Balfe. 1992. Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type 1 gp120. Virology. 191:732-742.
27. Gorny, M.K., A.J. Conley, S. Karwowska, A. Buchbinder, J.-Y. Xu, E.A. Emini, S. Koenig, and S. Zolla-Pazner. 1992. Neutralization of diverse human immunodeficiency virus typo 1 variants by an anti-V3 human monoclonal antibody. J. Virol 66:7538-7542.
28. Sun, N.C., D.D. Ho, C.R.Y. Sun, R.-S. Liou, W. Gordon, M.S.C. Fung, X.-L. Li, R.C. Ting, T.-H. Lee, N.T. Chang, and T.W. Chang. 1989. Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of HIV-1 gp120. J. Virol. 63:3579-3585.
29. McKeating, J.A., J.P. Moore, M. Ferguson, H.S. Marsden, S. Graham, J.W. Almond, D.J. Evans, and R.A. Weiss. 1992. Monoclonal antibodies to the C4 region of human immunodeficiency virus type 1 gp120: use in topological analysis of a CD4 binding site. AIDS Res. Human Retroviruses. 8:451-459.
30. Moore, J.P., M. Thali, B.A. Jameson, F. Vignaux, G K. Lewis, S.-W. Poon, M. Charles, M.S. Fung, B. Sun, P.J. Durda, et al. 1993. Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop. J. Virol. 67: 4785-4796.
31. Ho, D.D., J.A. McKeating, X.L. Li, T. Moudgil, E.S. Daar, N -C. Sun, and J.E. Robinson. 1991. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J. Virol. 65:489-493.
32. Thali, M., U. Olshevsky, C. Furman, D. Gabudza, M. Posner, and J. Sodroski. 1991. Characterization of a discontinuous human immunodeficiency virus type 1 epitope recognized by a broadly reactive neutralizing human monoclonal antibody. J. Virol. 65:6188-6193.
33. Thali, M., C. Furman, D.D. Ho, J. Robinson, S. Tilley, A. Pinter, and J. Sodroski. 1992. Discontinous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type-1 gp120 envelope glycoprotein J. Virol. 66:5635-5641.
34. Roben, P., J.P. Moore, M. Thali, J. Sodroski, C.F. Barbas, III, and D.R. Burton. 1994. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 J. Virol. 68:4821-4828.
35. Burton, D.R., J. Pyati, R. Koduri, S.J. Sharp, G.B. Thornion, P.W.H.I. Parren, L.S.W. Sawyer, R.M. Hendry, N. Dunlop, P.L. Nara, et al. 1994 Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science (Wash. DC). 266:1024-1027.
36. Ho, D.D., J.A. McKeating, X.-L. Li, T. Moudgil, E.S. Daar, N-C. Sun, and J.E. Robinson. 1991. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J. Virol. 65:489-493.
37. Thali, M., J.P. Moore, C. Furman, M. Charles, D.D. Ho, J. Robinson, and J. Sodroski. 1993. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67:3978-3988.
38. Moore, J.P., and P. Nara. 1991. The role of the V3 loop of gp120 in HIV infection. AIDS. 5(Suppl. 2):S21-S33.
39. Muster, T., F. Steindl, M. Purtscher, A. Trkola, A. Klima, G. Himmler, F. Ruker, and H. Katinger. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:6642-6647.
40. Conley, A.J., J.A. Kessler II, L.J. Boots, J.-S. Tung, B.A. Arnold, P.M. Keller, A.R. Shaw, and E.A. Emini. 1994. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc. Natl. Acad. Sci. USA. 91: 3348-3352.
41. Dalgleish, A.G., T.C. Chanh, R.C. Kennedy, P. Kanda, P.R. Clapham, and R.A. Weiss. 1988. Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide. Virology. 165:209-215.
42. Sattentau, Q.J., S. Zolla-Pazner, and P. Poignard. 1995. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology. 206:713-717.
43. Allan, J.S. 1991. Receptor-mediated activation of immunodeficiency viruses in viral fusion. Science (Wash. DC). 252: 1322.
44. Moore, J.P., J.A. McKeating, R.A. Weiss, P.R. Clapham, and Q.J. Sattentau. 1991. Model for receptor mediated activation of immunodeficiency viruses in viral fusion. Science (Wash. DC). 252:1322-1323.
45. Moore, J.P., B. Jameson, R.A Weiss, and Q.J. Sattentau. 1993. The HIV-cell fusion reaction. In Viral Fusion Mechanisms. J Bentz, editor. CRC Press, Inc., Boca Raton, FL. pp. 233-272.
46. Signoret, N., P. Poignard, D. Blanc, and Q.J. Sattentau. 1993. Human and simian immunodeficiency viruses: virus-receptor interactions. Trends Microbiol. 1:328-333.
47. Sattentau, Q.J., and J.P. Moore. 1991. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J. Exp. Med. 174:407-415.
48. Sattentau, Q.J., J.P. Moore, F. Vignaux, F. Traincard, and P. Poignard. 1993. Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding. J. Virol. 67:7383-7393.
49. Moore, J.P., J.A. McKeating, R.A. Weiss, and Q.J. Sattentau. 1990. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science (Wash. DC). 250:1139-1142.
50. Hart, T.K., R. Kirsh, H. Ellens, R.W. Sweet, D.M. Lambert, S.R. Petteway, J Leary, and P. Bugelski. 1991. Binding of soluble CD4 proteins to human immunodeficiency virus type-1 and infected cells induces release of envelope glycoprotein gp120. Proc. Natl. Acad. Sci. USA. 88:2189-2193.
51. Berger, E.A., J.D. Lifson, and L.E. Eiden. 1991. Stimulation of glycoprotein gp120 dissociation from the envelope glycoprotein complex of human immunodeficiency virus type 1 by soluble CD4 and CD4 peptide derivatives: implications for the role ot the complimentarity-determining region 3-like region in membrane fusion. Proc. Natl. Acad. Sci. USA. 88: 8082-8086.
52. Thali, M., C. Furman, E. Helseth, H. Repke, and J. Sodroski. 1992. Lack of correlation between soluble CD4-induced shedding of the human immunodeficiency virus type 1 exterior envelope glycoprotein and subsequent membrane fusion events. J. Virol. 66:5516-5524.
53. Fu, Y.-K., T.K. Hart, Z.L. Jonak, and P.J. Bugelski. 1993. Physicochemical dissociation of CD4-mediated syncytium formation and shedding of human immunodeficiency virus type 1 gp120. J. Virol. 67:3818-3825
54. Moore, J.P., J.A. McKeating, W.A. Norton, and Q.J. Sattentau. 1991. Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4. J. Virol. 65:1133-1140.
55. Dimitrov, D.S., K. Hillman, J. Manischewitz, R. Blumenthal, and Hana Golding. 1992. Correlation between kinetics of soluble CD4 interactions with HIV-1-env-expressing cells and inhibition of syncytia formation: implications for mechanisms of cell fusion and therapy for AIDS. AIDS. 6:249-256.
56. Orloff, S.L., M.S. Kennedy, A.A. Belperron, P.J. Maddon, and J.S. McDougal. 1993. Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4. J. Virol. 67: 1461-1471.
57. Moore, J.P., J.A. McKeating, Y. Huang, A. Ashkenazi, and D.D. Ho. 1992. Virions of human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein retention from sCD4-sensitive isolates. J. Virol. 66:235-243.
58. Moore, J.P., Y. Cao, L. Quing, Q.J. Sattentau, J Pyati, R. Kodun, J. Robinson, C.F. Barbas III, D.R. Burton, and D.D. Ho. 1995. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69: 101-109.
59. Sattentau, Q.J., and J.P. Moore. HIV-1 neutralization is determined by epitope exposure on the gp120 oligomer. J. Exp. Med. 182:185-196.
60. Moore, J.P., Q.J. Sattentau, R. Wyatt, and J. Sodroski. 1994. Mapping the topology of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies. J. Virol. 68:469-484.
61. Gorny, M.K., V. Gianakakos, S. Sharpe, and S. Zolla-Pazner. 1989. Generation of human monoclonal antibodies to human immunodeficiency virus. Proc. Natl. Acad. Sci. USA. 86: 1624-1628.
62. Fisher, A.G., E. Collati, L. Ratner, R.C. Gallo, and F. Wong-Staal. 1985. A molecular clone of HTLV-III with biological activity. Nature (Lond.). 316:262-265.
63. Willey, R.L., M.A. Martin, and K.W.C. Peden. 1994. Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type I. J. Virol. 68:1029-1039.
64. Prince, A.M., B. Horowitz, L. Baker, R.W. Shulman, H. Ralph, J. Valinsky, A. Cundell, B. Brotman, W. Boehle, F. Rey et al. 1988. Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV. Proc. Natl. Acad. Sci. USA. 85:6944-6948.
65. Clavel, F., and P. Chameau. 1994. Fusion from without directed by human immunodeficiency virus particles. J. Virol. 68:1179-1185.
66. Looney, D.J., S. Hayashi, M. Nicklas, R.R. Redfield, S. Broder, F. Wong-Staal, and H. Mitsuya. 1990. Differences in the interaction of HIV-1 and HIV-2 with CD4. J. Acq. Immun. Defic. Syndr. 3:649-657.
67. Sekigawa, I., S.M. Chamow, J.E. Groopman, and R.A. Byrn. 1990. CD4 immunoadhesin, but not recombinant soluble CD4, blocks syncytium formation by human immunodeficiency virus type-2 infected lymphoid cells. J. Virol. 64.5194-5198.
68. Clapham, P.R., J.N. Weber, D. Whitby, K. McIntosh, A.G. Dalgleish, P.J. Maddon, K.C. Deen, R.W. Sweet, and R.A. Weiss. 1989. Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. Nature (Lond.). 337:368-370.
69. Allan, J.S., E.M. Whitehead, K. Strout, M. Short. P. Kanda, T.K. Hart, and P.J. Bugelski. 1992. Strong association of simian immunodeficiency virus (SIVagm) envelope glycoprotein heterodimers: possible role in receptor-mediated activation. AIDS Res. Hum. Retroviruses. 8:2011-2020.
70. Allan, J.S., J. Strauss, and D.W. Buck. 1990. Enhancement of SIV infection with soluble receptor molecules. Science (Wash. DC). 247:1084-1088.
71. Werner, A., G. Winkowsky, and R. Kurth. 1990. Soluble CD4 enhances simian immunodeficiency virus SIVagm infection. J. Virol. 64:6252-6256.
72. Clapham, P.R., A. McKnight, and R.A. Weiss. 1992. Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4. J. Virol. 66:3531-3537.
73. Schutten, M., A.C. Andeweg, M.L. Bosch, and A.D.M.E. Osterhaus. 1994. Enhancement of infectiviry of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1. Scand. J. Immunol. 41: 18-22.
74. Sullivan, N., Y. Sun, J. Li, W. Hofmann, and J. Sodroski. 1995. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line passaged human immunodeficiency virus type 1 isolates. J. Virol. 69: 4413-4422.
75. Wyatt, R., J.P. Moore, M. Accola, E. Desjardin, J. Robinson, and J. Sodroski. 1995. The involvement of the V1/V2 variable loop structures in the exposure of HIV-1 gp120 epitopes induced by receptor binding. J. Virol. In press.
76. Choe, H.-R., and J. Sodroski. 1995. Adaptation of human immunodeficiency virus type 1 to cells expressing a binding-deficient CD4 mutant (lysine 46 to aspartic acid). J. Virol. 69: 2801-2810.
77. Wyatt, R., M. Thali, S. Tilley, A. Pinter, M. Posner, D. Ho, J. Robinson, and J. Sodroski. 1992. Relationship of human immunodeficiency virus type 1 gp120 third variable loop to a component ot the CD4 binding site in the fourth conserved region. J. Virol. 66:6997-7004.
78. Willey, R.L., E.K. Ross, A.J. Buckler-White, T.S. Theodore, and M.A. Martin. 1989. Functional interaction of constant and variable domains of human immunodeficiency virus type 1 gp120. J. Virol. 63:3595-3600.
79. Wyatt, R., N. Sullivan, M. Thali, H. Repke, D. Ho, J. Robinson, M. Posner, and J. Sodroski. 1993. Characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J. Virol. 67:4557-4565.